We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

48 hedge funds and large institutions have $49.8M invested in Ovid Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 7

2% less funds holding

Funds holding: 49 → 48 (-1)

3.15% less ownership

Funds ownership: 31.8% → 28.65% (-3.1%)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

35% less capital invested

Capital invested by funds: $77.2M → $49.8M (-$27.4M)

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
26
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.39M
2
Deutsche Bank
Deutsche Bank
Germany
+$685K
3
Jennison Associates
Jennison Associates
New York
+$588K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$538K
5
BCM
Bridgeway Capital Management
Texas
+$481K

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$6.64M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.21M
3
SFM
Sphera Funds Management
Israel
-$1.78M
4
CC
Casdin Capital
New York
-$1.58M
5
RG
Redmile Group
California
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$9.79M -$718K -88,807 -6%
BlackRock
2
BlackRock
New York
$9.61M +$2.39M +295,247 +28%
Jennison Associates
3
Jennison Associates
New York
$4.6M +$588K +72,651 +13%
TCM
4
Tekla Capital Management
Massachusetts
$3.79M – – –
O
5
OppenheimerFunds
New York
$3M -$4.45K -550 -0.1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.83M +$538K +66,464 +20%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$2.12M +$7.36K +910 +0.3%
Deutsche Bank
8
Deutsche Bank
Germany
$2.09M +$685K +84,621 +40%
DCM
9
Driehaus Capital Management
Illinois
$2.01M +$98.9K +12,221 +4%
BBA
10
Baker Bros. Advisors
New York
$1.75M -$693K -85,600 -26%
Ameriprise
11
Ameriprise
Minnesota
$1.47M -$63.1K -7,795 -4%
RG
12
Redmile Group
California
$1.14M -$1.23M -152,064 -49%
Northern Trust
13
Northern Trust
Illinois
$837K +$431K +53,264 +82%
BCM
14
Bridgeway Capital Management
Texas
$767K +$481K +59,440 +121%
State Street
15
State Street
Massachusetts
$747K +$244K +30,162 +40%
Millennium Management
16
Millennium Management
New York
$420K +$480K +59,344 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$353K +$130K +16,070 +47%
Charles Schwab
18
Charles Schwab
California
$243K +$112K +13,785 +67%
JP Morgan Chase
19
JP Morgan Chase
New York
$233K +$221K +27,343 +483%
Morgan Stanley
20
Morgan Stanley
New York
$196K +$8.2K +1,014 +4%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$180K +$96.2K +11,889 +88%
SSA
22
Schonfeld Strategic Advisors
New York
$145K – – –
SIM
23
Spark Investment Management
New York
$139K +$72.8K +9,000 +83%
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$132K +$79.1K +9,776 +110%
TCIM
25
TIAA CREF Investment Management
New York
$119K – – –
1
2 3

OVID Hedge Fund Activity: Q1 2018 in Review

48 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2018, worth a combined $49.8M — down 35% from $77.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of OVID and 9 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 26 added.

The largest buyer was BlackRock, adding an estimated $2.39M. The largest seller was Putnam Investments, exiting entirely with an estimated $6.64M sold.

  • 48 institutional investors held Ovid Therapeutics (OVID) as of Q1 2018, down from 49 in Q4 2017.
  • Funds reported $49.8M of Ovid Therapeutics stock for Q1 2018, down 35% quarter-over-quarter.
  • 9 funds opened new Ovid Therapeutics positions in Q1 2018 and 10 closed out, a net change of -1 holder.
  • The largest Ovid Therapeutics buyer in Q1 2018 was BlackRock, an estimated $2.39M added.
  • The largest Ovid Therapeutics seller in Q1 2018 was Putnam Investments, an estimated $6.64M sold.

Based on aggregated 13F filings for Q1 2018.